Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer
1997

Haematological Toxicity as a Marker for Chemotherapy Efficacy in Breast Cancer

Sample size: 211 publication Evidence: moderate

Author Information

Author(s): T Saarto, C Blomqvist, P Rissanen, A Auvinen, I Elomaa

Primary Institution: Helsinki University Central Hospital

Hypothesis

Does a lower leucocyte nadir during chemotherapy correlate with better survival outcomes in breast cancer patients?

Conclusion

Patients with a lower leucocyte nadir during chemotherapy had significantly better distant disease-free survival and overall survival.

Supporting Evidence

  • Lower leucocyte nadir was associated with better distant disease-free survival.
  • Statistically significant correlations were found between leucocyte nadir and overall survival.
  • The study included 211 patients with stage II and III breast cancer.

Takeaway

If patients have lower white blood cell counts during chemotherapy, they tend to do better in terms of staying cancer-free and living longer.

Methodology

Retrospective analysis of 211 breast cancer patients treated with adjuvant chemotherapy, assessing the correlation between leucocyte nadir and survival outcomes.

Potential Biases

Potential selection bias due to patient tolerance affecting dose intensity.

Limitations

The study is retrospective and may be influenced by selection bias.

Participant Demographics

Mean age of patients was 50.6 years; 48% were estrogen receptor positive and 45% were progesterone receptor positive.

Statistical Information

P-Value

0.006 for DDFS, 0.04 for OS

Confidence Interval

(1.13-1.78) for DDFS, (1.03-1.68) for OS

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication